Serelaxin (SLX)-based therapy for cardiomyocyte proliferation and heart regeneration: Serelaxin (SLX), a recombinant relaxin-2, decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/August/2018, 7.10 pm